Company profile for CTI BioPharma Corp

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

CTI BioPharma is a biopharmaceutical company whose mission is to acquire, develop and bring to market less toxic, more effective therapies to treat and cure cancer. Our therapeutic focus is on novel targeted therapies covering a spectrum of blood-related cancers. We see patients as people, looking at potential therapies from the patient’s perspective to address both the clinical need and the impact treatment can have on a pa...
CTI BioPharma is a biopharmaceutical company whose mission is to acquire, develop and bring to market less toxic, more effective therapies to treat and cure cancer. Our therapeutic focus is on novel targeted therapies covering a spectrum of blood-related cancers. We see patients as people, looking at potential therapies from the patient’s perspective to address both the clinical need and the impact treatment can have on a patient’s life. We prioritize the patient experience and are committed to developing therapeutic options for people living with cancer who want a chance at a longer and better quality of life.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
3101 Western Ave., #800 Seattle, WA 98121
Telephone
Telephone
+1 206-282-7100
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.prnewswire.com/news-releases/sobi-completes-acquisition-of-cti-biopharma-corp-301863272.html

PR NEWSWIRE
26 Jun 2023
In $1.7B buy, Sobi acquires CTI and myelofibrosis drug Vonjo
In $1.7B buy, Sobi acquires CTI and myelofibrosis drug Vonjo

11 May 2023

// Kevin Dunleavy FIERCE PHARMA

https://www.fiercepharma.com/pharma/sobi-snatches-cti-and-blood-cancer-drug-vonjo-17b-purchase

Kevin Dunleavy FIERCE PHARMA
11 May 2023

https://www.reuters.com/markets/deals/swedens-sobi-makes-17-bln-offer-buy-cti-biopharma-2023-05-10/

REUTERS
10 May 2023

https://www.prnewswire.com/news-releases/cti-biopharma-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-301816726.html

PR NEWSWIRE
05 May 2023

https://www.prnewswire.com/news-releases/cti-biopharma-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-301813803.html

PR NEWSWIRE
02 May 2023

https://www.prnewswire.com/news-releases/cti-biopharma-to-participate-in-two-upcoming-investor-conferences-in-april-2023-301796072.html

PR NEWSWIRE
12 Apr 2023

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty